The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 16, 2019

Filed:

Apr. 14, 2016
Applicants:

Julius-maximilians-universität Würzburg, Würzburg, DE;

Ignova Gmbh, Lyons, FR;

Inventors:

Günter Sprotte, Rottenbuch, DE;

Ana Maria Waaga-Gasser, Würzburg, DE;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); C07K 16/12 (2006.01); G01N 33/68 (2006.01); C07K 16/44 (2006.01); G01N 33/569 (2006.01); G01N 33/92 (2006.01); C12Q 1/6883 (2018.01); C12Q 1/6876 (2018.01);
U.S. Cl.
CPC ...
G01N 33/6863 (2013.01); C07K 16/1203 (2013.01); C07K 16/44 (2013.01); C12Q 1/6876 (2013.01); C12Q 1/6883 (2013.01); G01N 33/56911 (2013.01); G01N 33/6866 (2013.01); G01N 33/6869 (2013.01); G01N 33/92 (2013.01); A61K 2039/505 (2013.01); C07K 2317/11 (2013.01); C07K 2317/23 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/475 (2013.01); G01N 2333/4756 (2013.01); G01N 2333/521 (2013.01); G01N 2333/54 (2013.01); G01N 2333/5412 (2013.01); G01N 2333/5421 (2013.01); G01N 2333/5428 (2013.01); G01N 2333/56 (2013.01); G01N 2333/705 (2013.01); G01N 2333/70596 (2013.01); G01N 2333/916 (2013.01); G01N 2400/50 (2013.01); G01N 2800/125 (2013.01); G01N 2800/26 (2013.01); G01N 2800/52 (2013.01);
Abstract

The present invention relates to the biomarkers for predicting the clinical response to anti-LPS immunoglobulin treatments in patients in need thereof. In particular, the invention provides methods for predicting the clinical response to an anti-LPS immunoglobulin treatment in a patient in need thereof, said method comprising the steps of evaluating the expression of a predictive biomarker selected from the group consisting of CD14, CD68, TLR4, TLR7, IL6, IL8, IL10, IFN-alpha, IGF1, CXCL1, CXCL9, CXCL10, RAGE, GDNF, BCHE, and combination thereof, in said patient.


Find Patent Forward Citations

Loading…